In 2010, the US Congress enacted legislation to streamline the approval process for biosimilars of products losing patent protection, with the goal of decreasing costs and improving patient access to therapeutically important but expensive biologicals. In 2015, the US Food and Drug Administration (FDA) approved the first biosimilar through this pathway.

Approval of additional biosimilars in the US, including those used by nephrologists, is anticipated. Given the relative lack of knowledge regarding biosimilars, their approval process and a lack of trust by the nephrology community regarding their safety and efficacy, the National Kidney Foundation conducted a symposium ‘Introduction of Biosimilar Therapeutics into Nephrology Practice in the US’ on 17–18 September 2015 [1].

Issues related to manufacturing, regulatory approval process, interchangeability, substitution/switching, nomenclature, and clinician and patient awareness and acceptance were examined. This report summarizes the main discussions at the symposium, highlights several controversies and makes recommendations related to public policy, professional and patient education and research needs.

Once biosimilar erythropoiesis stimulating agents (ESAs) are approved in the US, decisions regarding their use will be a function of cost savings versus residual safety concerns. It is likely that health plans and dialysis providers will encourage the use of biosimilar ESAs by requiring less hassle and paperwork to prescribe them versus the reference agent, so interchangeability becomes less of a driver to the use of biosimilars than formulary decisions.

If a biosimilar ESA is deemed interchangeable, then the process for substitution at the pharmacy level will vary according to state law, but all states will allow the prescriber to prevent substitution by writing ‘dispense as written’ or something to that effect. If substitution does occur it will be vital for both the prescriber and patient to be informed so that any adverse reactions can be attributed to a specific agent. Pharmacovigilance to identify patterns and trends of adverse events will require unique identifiers for each agent.

Biosimilars are a new frontier of therapy in the US and constitute a learning, research and public policy opportunity for all stakeholders. The expansion of biosimilar ESAs into the US market should answer many questions regarding their efficacy, safety and pharmacoeconomics at a level of statistical power not previously achieved. In order for this to occur, the appropriate educational, investigative and policy (at the state and Federal level) infrastructure must be in place as these agents are approved.

Conflict of interest
Several of the authors of the research paper [1] reported conflicts of interest, including having worked as a consultant, as a clinical investigator and serving on the board of directors of various pharmaceutical companies. For full details of the authors’ conflicts of interest, see the research paper [1].

Abstracted by Jay Wish of Indiana University Health, Indianapolis, Indiana.

Editor’s comment
Readers interested to learn more about biosimilars are invited to visit www.gabi-journal.net to view the following manuscripts published in GaBI Journal:

Biosimilars in oncology: current and future perspectives

The ethics of biosimilars

GaBI Journal is indexed in Embase, Scopus, Thomson Reuters’ ESCI and more.

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal platform – please send us your submission here.

Related article
Biosimilars of epoetin alfa

Reference
1. Wish JB, Charytan C, Chertow GM, Kalantar-Zadeh K, Kliger AS, Rubin RJ, et al. Introduction of biosimilar therapeutics into nephrology practice in the United States: report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis. 2016. pii: S0272-6386(16)30346-8. doi: 10.1053/j.ajkd.2016.06.022 [Epub ahead of print]

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.